

Metabotropic Glutamate Receptor 2 - Pipeline Review, H2 2020

<https://marketpublishers.com/r/M15FD5D477BBEN.html>

Date: November 2020

Pages: 58

Price: US\$ 3,500.00 (Single User License)

ID: M15FD5D477BBEN

Abstracts

Metabotropic Glutamate Receptor 2 - Pipeline Review, H2 2020

SUMMARY

According to the recently published report 'Metabotropic Glutamate Receptor 2 - Pipeline Review, H2 2020'; Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) pipeline Target constitutes close to 12 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes.

Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Metabotropic glutamate receptor 2 is a protein encoded by the GRM2 gene. It is a receptor for glutamate. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors, such as adenylylase. Signaling inhibits adenylylase activity. May mediate suppression of neurotransmission or may be involved in synaptogenesis or synaptic stabilization.

The report 'Metabotropic Glutamate Receptor 2 - Pipeline Review, H2 2020' outlays comprehensive information on the Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in

Phase I, Preclinical and Discovery stages are 4, 6 and 1 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System which include indications Depression, Schizophrenia, Drug Addiction, Major Depressive Disorder, Treatment Resistant Depression, Alzheimer's Disease, Anxiety Disorders, Epilepsy, Mild Cognitive Impairment, Nicotine Addiction, Panic Disorders, Parkinson's Disease, Post-Traumatic Stress Disorder (PTSD), Psychosis and Sleep Disorders.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2)

The report reviews Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics and enlists all their major and minor projects

The report assesses Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Metabotropic Glutamate

Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Overview

Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Therapeutics

Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Therapeutics

Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Companies

Involved in Therapeutics Development

Addex Therapeutics Ltd

Bristol-Myers Squibb Co

Camino Pharma LLC

Denovo Biopharma LLC

Eli Lilly and Co

Gate Neurosciences Inc

Johnson & Johnson

Merck & Co Inc

Taisho Pharmaceutical Holdings Co Ltd

Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Drug Profiles

BMT-133218 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GATE-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JNJ-40411813 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JNJ-5515 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LY-3020371 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MGS-0274 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pomaglumetad methionil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SBP-0069330 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SBP-9881 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize Metabotropic Glutamate Receptor 2 for Psychosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize mGlu2 for Anxiety and Depression - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize MGLUR2 for Cardiovascular and Central Nervous System Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Dormant Products

Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Discontinued Products

Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Product Development Milestones

Featured News & Press Releases

Jun 30, 2020: Camino Pharma receives \$920K Small Business Innovation Research (SBIR) grant from the National Institute of Mental Health

Jun 16, 2020: Addex mGlu2 PAM program to advance into Epilepsy Phase 2a proof of concept clinical study

Oct 02, 2018: Addex selective mGlu2 PAM ADX71149 included in review highlighting promising investigative drugs for epilepsy

Sep 04, 2018: Addex's selective mGlu2 PAM ADX71149 shows promise in treating severe panic disorders and PTSD

Feb 27, 2017: Addex's ADX71149 Anti-Epileptic Effect Highlighted in Scientific Journal, Epilepsia

Sep 23, 2015: Addex ADX71149 Demonstrates Synergistic Efficacy with Levetiracetam in Preclinical Models of Epilepsy

Feb 07, 2014: Addex Reports Top-line Data from ADX71149 Phase 2a Study in Patients with Major Depressive Disorder with Significant Anxiety Symptoms

Oct 29, 2013: Addex Licensee Completes Enrolment of 120 Patients in a Phase 2 Clinical Trial of ADX71149 for the Treatment of Anxious Depression

Nov 05, 2012: Addex Reports Top-line Data From Successful Phase IIa Clinical Study With ADX71149 In Schizophrenia Patients

Nov 05, 2012: Addex Therapeutics Reports Top-line Data From Phase IIa Clinical Study With ADX71149 In Schizophrenia Patients

Sep 17, 2012: Addex Partner Doses First Patient In Phase II Clinical Study Of ADX71149 For Treatment Of Major Depressive Disorder Patients With Anxiety Symptoms

Aug 29, 2012: Lilly Stops Phase III Development Of Pomaglometad Methionil For Treatment Of Schizophrenia Based On Efficacy Results

Jul 11, 2012: Lilly Announces Pomaglometad Methionil Did Not Meet Primary Endpoint Of Clinical Study

Jun 05, 2012: Janssen To Initiate Phase II Clinical Trial Of ADX71149 For Treatment Of Major Depressive Disorder With Anxiety Symptoms

Mar 28, 2011: Addex Partner Starts Phase IIa Clinical Trial Of ADX71149 In Schizophrenia

Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Indication, H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Number of Products under Investigation by Universities/Institutes, H2 2020
Products under Investigation by Universities/Institutes, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Pipeline by Addex Therapeutics Ltd, H2 2020
Pipeline by Bristol-Myers Squibb Co, H2 2020
Pipeline by Camino Pharma LLC, H2 2020
Pipeline by Denovo Biopharma LLC, H2 2020
Pipeline by Eli Lilly and Co, H2 2020
Pipeline by Gate Neurosciences Inc, H2 2020
Pipeline by Johnson & Johnson, H2 2020
Pipeline by Merck & Co Inc, H2 2020
Pipeline by Taisho Pharmaceutical Holdings Co Ltd, H2 2020
Dormant Products, H2 2020
Dormant Products, H2 2020 (Contd..1), H2 2020
Dormant Products, H2 2020 (Contd..2), H2 2020
Discontinued Products, H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2020

Number of Products under Development by Top 10 Indications, H2 2020

Number of Products by Mechanism of Actions, H2 2020

Number of Products by Stage and Mechanism of Actions, H2 2020

Number of Products by Routes of Administration, H2 2020

Number of Products by Stage and Routes of Administration, H2 2020

Number of Products by Stage and Molecule Type, H2 2020

I would like to order

Product name: Metabotropic Glutamate Receptor 2 - Pipeline Review, H2 2020

Product link: <https://marketpublishers.com/r/M15FD5D477BBEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M15FD5D477BBEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970